Zhao Lu1, Pu Cheng1, Fu Yang1, Zhaoxu Zheng1, Xishan Wang1. 1. Department of Colorectal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Abstract
OBJECTIVE: For patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy (NCRT), significant pathological response of the primary tumor has been proposed to identify candidates for organ preservation. However, this does not address metastatic lymph nodes in the mesorectum. The aim of this study was to assess the incidence of lymph node metastases in ypT0 patients treated with NCRT and curative resection and to explore risk factors associated with survival. METHODS: This was a retrospective study of patients with ypT0 rectal cancer after NCRT and curative resection at a tertiary care center in China from 2005 to 2014. RESULTS: A total of 60 (18.6%) patients who underwent surgery after NCRT and achieved ypT0 were enrolled in this study; one patient was excluded owing to lack of follow-up. Of these 59 patients, lymph node metastases were found in the mesorectum (ypT0N+) in eight (13.6%) patients. After a median follow-up of 52 months, 5-year recurrence-free survival (82.7% vs. 62.5%, P=0.014) and overall survival (OS) (90.9% vs. 70.0%, P=0.032) were much higher in ypN0 than ypN+ patients. Multivariate analyses showed that ypN+ status (P=0.009) and perioperative blood transfusion (BT) (P=0.001) were significantly independent risk factors associated with recurrence; however, no factor was correlated with 5-year OS. CONCLUSIONS: Patients with ypT0N0 rectal cancer can achieve excellent long-term outcomes; however, positive lymph nodes or tumor deposits can still be found in 13.6% of ypT0 patients. Nodal positivity in the mesorectum and perioperative BT are independent risk factors for recurrence.
OBJECTIVE: For patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy (NCRT), significant pathological response of the primary tumor has been proposed to identify candidates for organ preservation. However, this does not address metastatic lymph nodes in the mesorectum. The aim of this study was to assess the incidence of lymph node metastases in ypT0 patients treated with NCRT and curative resection and to explore risk factors associated with survival. METHODS: This was a retrospective study of patients with ypT0 rectal cancer after NCRT and curative resection at a tertiary care center in China from 2005 to 2014. RESULTS: A total of 60 (18.6%) patients who underwent surgery after NCRT and achieved ypT0 were enrolled in this study; one patient was excluded owing to lack of follow-up. Of these 59 patients, lymph node metastases were found in the mesorectum (ypT0N+) in eight (13.6%) patients. After a median follow-up of 52 months, 5-year recurrence-free survival (82.7% vs. 62.5%, P=0.014) and overall survival (OS) (90.9% vs. 70.0%, P=0.032) were much higher in ypN0 than ypN+ patients. Multivariate analyses showed that ypN+ status (P=0.009) and perioperative blood transfusion (BT) (P=0.001) were significantly independent risk factors associated with recurrence; however, no factor was correlated with 5-year OS. CONCLUSIONS: Patients with ypT0N0 rectal cancer can achieve excellent long-term outcomes; however, positive lymph nodes or tumor deposits can still be found in 13.6% of ypT0 patients. Nodal positivity in the mesorectum and perioperative BT are independent risk factors for recurrence.
Authors: Carlo Capirci; Vincenzo Valentini; Luca Cionini; Antonino De Paoli; Claus Rodel; Robert Glynne-Jones; Claudio Coco; Mario Romano; Giovanna Mantello; Silvia Palazzi; Falchetti Osti Mattia; Maria Luisa Friso; Domenico Genovesi; Cristiana Vidali; Maria Antonietta Gambacorta; Alberto Buffoli; Marco Lupattelli; Maria Silvia Favretto; Giuseppe La Torre Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-11 Impact factor: 7.038
Authors: Luigi Zorcolo; Alan S Rosman; Angelo Restivo; Michele Pisano; Giuseppe R Nigri; Alessandro Fancellu; Marcovalerio Melis Journal: Ann Surg Oncol Date: 2012-03-21 Impact factor: 5.344
Authors: C J Kim; T J Yeatman; D Coppola; A Trotti; B Williams; J S Barthel; W Dinwoodie; R C Karl; J Marcet Journal: Ann Surg Date: 2001-09 Impact factor: 12.969
Authors: Rene Warschkow; Ulrich Güller; Dieter Köberle; Sascha A Müller; Thomas Steffen; Martin Thurnheer; Bruno M Schmied; Ignazio Tarantino Journal: Ann Surg Date: 2014-01 Impact factor: 12.969
Authors: Milou H Martens; Monique Maas; Luc A Heijnen; Doenja M J Lambregts; Jeroen W A Leijtens; Laurents P S Stassen; Stephanie O Breukink; Christiaan Hoff; Eric J Belgers; Jarno Melenhorst; Rob Jansen; Jeroen Buijsen; Ton G M Hoofwijk; Regina G H Beets-Tan; Geerard L Beets Journal: J Natl Cancer Inst Date: 2016-08-10 Impact factor: 13.506
Authors: Guillaume Martel; Youssuf Al-Suhaibani; Husein Moloo; Fatima Haggar; Martin Friedlich; Joseph Mamazza; Eric C Poulin; Hartley Stern; Robin P Boushey Journal: Dis Colon Rectum Date: 2008-06-04 Impact factor: 4.585
Authors: In Ja Park; Y Nancy You; John M Skibber; Miguel A Rodriguez-Bigas; Barry Feig; Sa Nguyen; Chung-Yuan Hu; George J Chang Journal: Dis Colon Rectum Date: 2013-02 Impact factor: 4.585
Authors: Hyuk Hur; Min Soo Cho; Woong Sub Koom; Joon Seok Lim; Tae Il Kim; Joong Bae Ahn; Hoguen Kim; Nam Kyu Kim Journal: Chin J Cancer Res Date: 2020-04 Impact factor: 5.087